Role of the renin-angiotensin-aldosterone system in the management of neonatal heart failure

Mitali Sahni, Priyanka Asrani, Sunil Jain

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Heart failure (HF) is common in the neonatal and pediatric populations. Despite advances in the management of HF, this disease carries significant mortality, morbidity, and socioeconomic burden. The renin-angiotensin-aldosterone system is a therapeutic target in the treatment of HF. In adults, significant advances have been made in the management of HF by targeting the renin-angiotensin-aldosterone system using angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists. Only angiotensin-converting enzyme inhibitors have been used in the pediatric population with HF. In this review, we provide an in-depth update on the pathophysiology of HF and discuss the potential future uses of newer and novel pharmacologic interventions in the management of HF in pediatric patients.

Original languageEnglish (US)
Pages (from-to)e575-e585
JournalNeoReviews
Volume16
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Renin-Angiotensin System
Heart Failure
Pediatrics
Angiotensin-Converting Enzyme Inhibitors
Mineralocorticoid Receptor Antagonists
Angiotensin Receptor Antagonists
Treatment Failure
Population
Heart Diseases
Morbidity
Mortality

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Role of the renin-angiotensin-aldosterone system in the management of neonatal heart failure. / Sahni, Mitali; Asrani, Priyanka; Jain, Sunil.

In: NeoReviews, Vol. 16, No. 10, 01.10.2015, p. e575-e585.

Research output: Contribution to journalArticle

Sahni, Mitali ; Asrani, Priyanka ; Jain, Sunil. / Role of the renin-angiotensin-aldosterone system in the management of neonatal heart failure. In: NeoReviews. 2015 ; Vol. 16, No. 10. pp. e575-e585.
@article{2885ae7046aa4530a30ea25b50a49d85,
title = "Role of the renin-angiotensin-aldosterone system in the management of neonatal heart failure",
abstract = "Heart failure (HF) is common in the neonatal and pediatric populations. Despite advances in the management of HF, this disease carries significant mortality, morbidity, and socioeconomic burden. The renin-angiotensin-aldosterone system is a therapeutic target in the treatment of HF. In adults, significant advances have been made in the management of HF by targeting the renin-angiotensin-aldosterone system using angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists. Only angiotensin-converting enzyme inhibitors have been used in the pediatric population with HF. In this review, we provide an in-depth update on the pathophysiology of HF and discuss the potential future uses of newer and novel pharmacologic interventions in the management of HF in pediatric patients.",
author = "Mitali Sahni and Priyanka Asrani and Sunil Jain",
year = "2015",
month = "10",
day = "1",
doi = "10.1542/neo.16-10-e575",
language = "English (US)",
volume = "16",
pages = "e575--e585",
journal = "Pediatrics in Review",
issn = "0191-9601",
publisher = "American Academy of Pediatrics",
number = "10",

}

TY - JOUR

T1 - Role of the renin-angiotensin-aldosterone system in the management of neonatal heart failure

AU - Sahni, Mitali

AU - Asrani, Priyanka

AU - Jain, Sunil

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Heart failure (HF) is common in the neonatal and pediatric populations. Despite advances in the management of HF, this disease carries significant mortality, morbidity, and socioeconomic burden. The renin-angiotensin-aldosterone system is a therapeutic target in the treatment of HF. In adults, significant advances have been made in the management of HF by targeting the renin-angiotensin-aldosterone system using angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists. Only angiotensin-converting enzyme inhibitors have been used in the pediatric population with HF. In this review, we provide an in-depth update on the pathophysiology of HF and discuss the potential future uses of newer and novel pharmacologic interventions in the management of HF in pediatric patients.

AB - Heart failure (HF) is common in the neonatal and pediatric populations. Despite advances in the management of HF, this disease carries significant mortality, morbidity, and socioeconomic burden. The renin-angiotensin-aldosterone system is a therapeutic target in the treatment of HF. In adults, significant advances have been made in the management of HF by targeting the renin-angiotensin-aldosterone system using angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists. Only angiotensin-converting enzyme inhibitors have been used in the pediatric population with HF. In this review, we provide an in-depth update on the pathophysiology of HF and discuss the potential future uses of newer and novel pharmacologic interventions in the management of HF in pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=84962339385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962339385&partnerID=8YFLogxK

U2 - 10.1542/neo.16-10-e575

DO - 10.1542/neo.16-10-e575

M3 - Article

VL - 16

SP - e575-e585

JO - Pediatrics in Review

JF - Pediatrics in Review

SN - 0191-9601

IS - 10

ER -